Amylyx Pharmaceuticals priced an upsized underwritten public offering expected to generate $500.2 million in gross proceeds, the company announced August 19, 2026, a day after reporting positive phase 3 (LUCIDITY) results for avexitide in post-bariatric hypoglycemia (PBH).¹ Amylyx said it will use the proceeds to fund pre-commercial activities for avexitide, including securing additional manufacturing capacity, along with research and development and working capital.¹
Key facts
- Drug: Avexitide (Amylyx Pharmaceuticals)
- Class: First-in-class GLP-1 receptor antagonist
- Indication studied: Post-bariatric hypoglycemia (PBH)
- Trial: LUCIDITY (NCT06747468); phase 3, 78 patients
- Primary endpoint met: 55% reduction in level 2/3 hypoglycemic events vs placebo (p=0.000003)
- Safety: Generally well tolerated; no treatment-related serious adverse events
- Disease burden: Affects ~8% of US bariatric surgery patients (~160,000 people)
- Regulatory status: FDA breakthrough therapy and orphan drug designations; NDA planned by end of 2026
- Financing: $500.2 million public offering; expected to close August 21, 2026
- Geography: US trial sites; potential 2027 US launch if approved
What did the phase 3 LUCIDITY trial show?
The phase 3 LUCIDITY trial (NCT06747468) enrolled 78 adults with PBH following Roux-en-Y gastric bypass surgery, randomized 3:2 to receive 90 mg avexitide subcutaneously once daily or placebo.² The trial met its FDA-agreed-upon primary endpoint, showing a 55% reduction in the composite rate of level 2 and level 3 hypoglycemic events compared with placebo through week 16 (p=0.000003).²
LUCIDITY also met all secondary endpoints, with consistent, statistically significant reductions across level 2 events measured by self-monitoring of blood glucose, level 2 events measured by continuous glucose monitoring, and independently adjudicated level 3 events.² Avexitide was generally well tolerated, with mostly mild to moderate adverse events and no serious adverse events related to treatment. The most common adverse events reported were diarrhea, injection site erythema, and injection site bruising.²
Why does this matter for patients with PBH?
PBH is a chronic metabolic condition estimated to affect about 8% of people in the United States who have undergone sleeve gastrectomy or Roux-en-Y gastric bypass surgery, or approximately 160,000 people.² The condition is driven by an exaggerated GLP-1 response that leads to excessive insulin secretion and recurrent, often severe drops in blood glucose. Level 2 and level 3 hypoglycemic events can cause confusion, loss of consciousness, and seizures, and there are currently no FDA-approved therapies for PBH.²
